Response to Ranibizumab Therapy in Neovascular AMD – An Evaluation of Good and Bad Responders

Menghini, Moreno; Kurz–Levin, M.; Amstutz, Christoph; Michels, S.; Windisch, Roman; Barthelmes, Daniel; Sutter, Florian

doi:10.1055/s-0029-1245203

Cited by 24 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, a local condition different in both eyes has to be suspected to be responsible for the reduced effect of anti-VEGF. In accordance with prior publications in the current study, better baseline distance acuity values were also correlated with the number of non-responders 13. This was expected, because eyes showing good distance acuity have a better chance to lose more than three lines than those with already devastated function.…”

Section: Discussionsupporting

confidence: 92%

Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration

et al. 2013

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration

et al. 2013

View full text Add to dashboard Cite

“…Baseline variables that predict treatment response have not yet been established, although the response in the first 3 months of treatment may indicate the future response (Menghini et al 2010). Therefore, treatment regimens should ideally be developed on an individual patient basis to ensure that patients receive sufficient retreatment.…”

Section: Discussionmentioning

confidence: 99%

Three‐year results of visual outcome with disease activity–guided ranibizumab algorithm for the treatment of exudative age‐related macular degeneration

Ćeklić

Framme

Wolf-Schnurrbusch

et al. 2012

Acta Ophthalmologica

View full text Add to dashboard Cite

. Purpose: To evaluate 3‐year follow‐up treatment outcomes with ranibizumab (Lucentis®) 0.5 mg administered either monthly or quarterly on a pro re nata (PRN) basis according to a disease activity–guided monitoring and treatment algorithm. Methods: A total of 316 treatment‐naive eyes of 316 patients with exudative age‐related macular degeneration met the criteria for inclusion in this retrospective, interventional case series. Patients were treated with ranibizumab 0.5 mg according to a disease activity–guided algorithm with monthly monitoring. Optical coherence tomography and fluorescein angiography were routinely used to assess disease activity: active lesions were treated with a series of three monthly injections, whereas inactive lesions were treated with quarterly injections. Results: Mean Early Treatment Diabetic Retinopathy Study best‐corrected visual acuity improved from 52 letters at baseline to 59 letters at 12 months, achieved with a mean of 7.1 injections, 61 letters at 24 months with a mean of 5.0 injections administered in the second year and 60 letters at 36 months with a mean number of 5.2 injections. Conclusions: Monthly visits and a morphology‐driven PRN regimen with 3 injections in case of recurrence plus quarterly injections in case of inactive CNV resulted in an average VA gain of 7–9 letters that could be maintained over 3 years.

show abstract

“…Bu ça-lışmada son anatomik ve fonksiyonel başarı ile cinsiyet, KNVM tipi ve yaş arasında anlamlı bir ilişki bulunamamıştır. Menghini ve arkadaşları başlangıç görmesi keskinliği düşük olan hastalarda görme kazanımını daha fazla bulmuşlardır [19]. Shona ve ark da başlangıç görmesi 24-34 harf olan olgular-da +14 harf, 35-54 harf olanlarda +7,1 harf ve 55 harf üzeri olanlarda ise +2,5 harflik bir görme artışı bildirmektedirler [20].…”

Section: Discussionunclassified

Neovasküler tip yaşa bağlı makula dejenerasyonunda intravitreal ranibizumab uygulamalarında tedavi etkinliği ve rekürrens üzerinde etkili olan faktörler

Kuru¹,

Erden²,

Elçioğlu³

2015

Dicle Med J

View full text Add to dashboard Cite

Objective: To evaluate the efficacy of intravitreal ranibizumab treatment and factors affecting the treatment in neovascular type age-related macular degeneration Methods: Ranibizumab injected 60 eyes of 60 patients with the diagnosis of neovascular age-related macular degeneration in our clinic were analyzed retrospectively. After three consecutive 3-month follow-up dose injection, decision to perform re-injections was according to best corrected visual acuity, fundus fluorescein angiography and optical coherence tomography findings in consecutive month follow-up. Patients were evaluated in terms of number of ranibizumab injections, pre-treatment and follow-up best-corrected visual acuity, central macular thickness, factors affecting the treatment and recurrence.Results: 30 (50%) of patients were male and 30 (50%) were women with a mean age of 67 ± 9.14 (50-84). While pretreatment visual acuity average of the cases was 1.12 ± 0.69 logMAR, at the end of 12th month was 0.92 ± 0.63 logMAR. While pre-treatment mean central macular thickness was 343.1 ± 97 µm, in the 12 th month was 286 ± 75.5 µm. While the first 3 injections were enough in 20 (33.3%) eyes, but 40 (66.7%) eyes had to be re-injected. Average number of injections was 4.23 ± 1.21. While there was no significant correlation between recent functional and anatomical success with age, gender, type of lens and membrane type, more vision gain was obtained in patients with initial lower visual acuity. The age of patients, pre-treatment visual acuity, membrane type were found to have no significant effect on recurrence rate. Membranes with classic component required more injection than occult type. Conclusion:After intravitreal injection of ranibizumab which is safe and effective in neovascular type of age-related macular degeneration more vision gain was obtained in patients with initial lower visual acuity and presence of classic component initial higher visual acuity, lower age required more injection.Key words: Age-related macular degeneration, ranibizumab, vascular endothelial growth factor ÖZET Amaç: Neovasküler tip yaşa bağlı maküla dejenerasyonu (YBMD) nedeniyle uygulanan intravitreal ranibizumab enjeksiyonunun etkinliğini ve tedavi üzerinde etkili olan faktörleri değerlendirmek Yöntemler: Kliniğimizde neovasküler tip YBMD'de intravitreal ranibizumab enjeksiyonu uygulanan 60 hastanın 60 gözü retrospektif olarak incelendi. Hastalara birer ay arayla 3 doz enjeksiyon yapıldıktan sonra aylık takiplerde en iyi düzeltilmiş görme keskinliği (EİDGK), fundus fluoresein anjiografi (FFA) ve optik kohorens tomografi (OKT) bulgularına göre enjeksiyon tekrarı uygulandı. Hastalar; enjeksiyon sayısı, takip süresi, tedavi öncesi ve kontrollerdeki EİDGK, santral makula kalınlığı (SMK), başarıda, rekürrens üzerinde etkili olan faktörler açısından değerlendirildi. Bulgular: 30'u (%50) erkek 30'u (%50) kadın olan hastaların ortalama yaşı 67±9,14 (50-84) yıl idi. Olgulardaki tedavi öncesi ortalama görme keskinliği 1,12 ± 0,69 logMAR iken 12. ayda ise, 0,92 ± 0,63 lo...

show abstract

Response to Ranibizumab Therapy in Neovascular AMD – An Evaluation of Good and Bad Responders

Cited by 24 publications

References 8 publications

Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration

Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration

Three‐year results of visual outcome with disease activity–guided ranibizumab algorithm for the treatment of exudative age‐related macular degeneration

Neovasküler tip yaşa bağlı makula dejenerasyonunda intravitreal ranibizumab uygulamalarında tedavi etkinliği ve rekürrens üzerinde etkili olan faktörler

Contact Info

Product

Resources

About